Form 8-K - Current report:
SEC Accession No. 0001140361-24-047980
Filing Date
2024-11-27
Accepted
2024-11-27 16:25:26
Documents
16
Period of Report
2024-11-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20036484x4_8k.htm   iXBRL 8-K 33833
2 EXHIBIT 1.1 ny20036484x4_ex1-1.htm EX-1.1 258162
3 EXHIBIT 5.1 ny20036484x4_ex5-1.htm EX-5.1 8952
7 ny20036484x4_ex5-1logo01.jpg GRAPHIC 34999
  Complete submission text file 0001140361-24-047980.txt   556771

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gyre-20241127.xsd EX-101.SCH 4025
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20241127_lab.xml EX-101.LAB 21967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20241127_pre.xml EX-101.PRE 16073
19 EXTRACTED XBRL INSTANCE DOCUMENT ny20036484x4_8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 241511555
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)